Related references
Note: Only part of the references are listed.Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients
M. Scartozzi et al.
BRITISH JOURNAL OF CANCER (2012)
Prediction of early death among patients enrolled in phase I trials: development and validation of a new model based on platelet count and albumin
A. Ploquin et al.
BRITISH JOURNAL OF CANCER (2012)
Validation of the royal marsden hospital prognostic score in patients treated in the phase I clinical trials program at the MD Anderson Cancer Center
Ignacio Garrido-Laguna et al.
CANCER (2012)
Pitfalls and limitations of a single-centre, retrospectively derived prognostic score for Phase I oncology trial participants - Reply to Fussenich et al.: A new, simple and objective prognostic score for Phase I cancer patients
David Olmos et al.
EUROPEAN JOURNAL OF CANCER (2012)
Patient Selection for Oncology Phase I Trials: A Multi-Institutional Study of Prognostic Factors
David Olmos et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Early mortality and overall survival in oncology phase I trial participants: can we improve patient selection?
Nicole G. Chau et al.
BMC CANCER (2011)
Translational imaging endpoints to predict treatment response to novel targeted anticancer agents
Natalie J. Serkova
DRUG RESISTANCE UPDATES (2011)
A new, simple and objective prognostic score for phase I cancer patients
L. M. Fussenich et al.
EUROPEAN JOURNAL OF CANCER (2011)
Development and Validation of a Prognostic Nomogram for Terminally Ill Cancer Patients
Jaime Feliu et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
Development and validation of a model that predicts early death among cancer patients participating in phase I clinical trials investigating cytotoxics
Nicolas Penel et al.
INVESTIGATIONAL NEW DRUGS (2010)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Prospective Validation of a Prognostic Score to Improve Patient Selection for Oncology Phase I Trials
Hendrik-Tobias Arkenau et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Participants in phase 1 oncology research trials - Are they vulnerable?
Justine Seidenfeld et al.
ARCHIVES OF INTERNAL MEDICINE (2008)
Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience
H-T Arkenau et al.
BRITISH JOURNAL OF CANCER (2008)
Identification of factors limiting patient recruitment into phase I trials: A study from the Royal Marsden Hospital
Vasilios Karavasilis et al.
EUROPEAN JOURNAL OF CANCER (2008)
90-Days mortality rate in patients treated within the context of a phase-I trial: How should we identify patients who should not go on trial?
Hendrik-Tobias Arkenau et al.
EUROPEAN JOURNAL OF CANCER (2008)
Prognostic factors among cancer patients with good performance status screened for phase I trials
Nicolas Penel et al.
INVESTIGATIONAL NEW DRUGS (2008)
Hypoxia-induced lactate dehydrogenase expression and tumor angiogenesis
Stephen A. Colgan et al.
CLINICAL COLORECTAL CANCER (2007)
Barriers in phase I cancer clinical trials referrals and enrollment: five-year experience at the Princess Margaret Hospital
Jeremy Ho et al.
BMC CANCER (2006)
Risks and benefits of phase 1 oncology trials, 1991 through 2002
E Horstmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Overall C as a measure of discrimination in survival analysis:: model specific population value and confidence interval estimation
MJ Pencina et al.
STATISTICS IN MEDICINE (2004)
Prognostic factors in pancreatic carcinoma - Serum LDH levels predict survival in metastatic disease
F Tas et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2001)
Multivariable analysis of prognostic factors for toxicity and survival for patients enrolled in phase I clinical trials
T Bachelot et al.
ANNALS OF ONCOLOGY (2000)
Share Paper
